Ecnoglutide Improves Glycemic Control and Reduces Body Weight, suggests study

A new systematic review and meta-analysis published in the journal of Frontiers in Endocrinology found that ecnoglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, may significantly improve blood-sugar control and reduce body weight in adults with type 2 diabetes. However, the findings cautioned that the available evidence remains limited and needs confirmation through larger, multicenter clinical trials.

The study reviewed randomized controlled trials identified through PubMed, Web of Science, Embase and the Cochrane Library, with searches updated through February 2026. 3 trials involving 977 participants were included which compared ecnoglutide with either placebo or the active diabetes treatment dulaglutide.

When compared with placebo, ecnoglutide was associated with a substantial reduction in glycated hemoglobin (HbA1c), a key measure of average blood-glucose levels. The pooled analysis found an average HbA1c reduction of 1.40 percentage points. Ecnoglutide also lowered fasting plasma glucose by 1.98 mmol/L and postprandial glucose by 4.88 mmol/L. The participants receiving ecnoglutide experienced an average body-weight reduction of 2.16 kilograms when compared to those receiving placebo.

Between doses of 0.4 mg and 1.2 mg, ecnoglutide demonstrated a dose-dependent relationship for HbA1c, fasting glucose and body weight, meaning greater doses were associated with larger improvements in these measures. Post-meal glucose appeared to be less strongly influenced by dose. Time-response analysis showed that the glucose-lowering effect increased over time and appeared to reach its peak around week 35 before leveling off. In contrast, body weight continued to decline in a sustained, approximately linear pattern during the period studied.

Adverse events occurred more frequently among participants receiving ecnoglutide than those receiving placebo, with the analysis estimating about twice the odds of experiencing an adverse event. However, this research found no statistically significant difference in serious adverse events between the groups.

Overall, the findings suggest that ecnoglutide could offer benefits across several important treatment outcomes in type 2 diabetes, particularly glycemic control and body-weight reduction. Further large-scale, multicenter randomized controlled trials will be needed to clarify long-term effectiveness, safety profile and optimal dosing and treatment duration of ecnoglutide before firmer conclusions can be drawn.

Source:

Feng, Y., Sun, C., Li, X., Hu, L., Zhou, K., Li, L., Yuan, Y., Yu, L., Wu, M., & Liu, L. (2026). Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy. Frontiers in Endocrinology, 17, 1934027. https://doi.org/10.3389/fendo.2026.1934027